Melatonin in aging and neurodegeneration

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 482-490

  Savaskan, Egemen ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Alzheimer' disease; Melatonin; Neuroprotection

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIOXIDANT; DOPAMINE; FREE RADICAL; GLUTATHIONE PEROXIDASE; MELATONIN; MELATONIN RECEPTOR; MELATONIN RECEPTOR 1A; MELATONIN RECEPTOR 1B; MELATONIN RECEPTOR 1C; NEUROPROTECTIVE AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BRAIN BLOOD FLOW; BRAIN REGION; CIRCADIAN RHYTHM; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; HOMEOSTASIS; HORMONE ACTION; HUMAN; MEMORY; NERVE DEGENERATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHOTORECEPTOR CELL; PROTEIN LOCALIZATION; RETINA; REVIEW; SCAVENGING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SLEEP WAKING CYCLE; SUPRACHIASMATIC NUCLEUS;

EID: 0036660006     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10104     Document Type: Review

References (94)

1. Acuña-Castroviejo D, Reiter RJ, Menendez-Pelaez A, Pablos MI, Burgos A. 1994. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J Pineal Res 16:100-112.
2. Acuña-Castroviejo D, Coto-Montes A, Gaia Monti M, Ortiz GG, Reiter RJ. 1997. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 60:PL23-29.
3. Acuña-Castroviejo D, Martin M, Macías M, Escames G, León J, Khaldy H, Reiter RJ. 2001. Melatonin, mitochondria, and cellular bioenergeties. J Pineal Res 30:65-74.
4. Al-Ghoul WM, Herman MD, Dubocovich ML. 1998. Melatonin receptor subtype expression in human cerebellum. Neuroreport 9:4063-4068.
5. Ancoli-Israel S, Klauber MR, Jones DW, Kripke DF, Martin J, Mason W, Pat-Horenezyk R, Fell R. 1997. Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep 20:18-23.
6. Antoniadis EA, Ko CH, Ralph MR, McDonald RJ. 2000. Circadian rhythms and memory. Behav Brain Res 11:25-37.
7. Armstrong SM. 1991. Treatment of sleep disorders by melatonin administration. In: Foldes A, Reiter RJ, editors. Advances in pineal research. London: J. Libbey and Co. p 263-274.
8. Axelrod J. 1974. The pineal gland: a neurochemical transducer. Science 184:1341-1344.
9. Bartness TJ, Goldman BD. 1989. Mammalian pineal melatonin: a clock for all seasons. Experientia 45:939-945.
10. Blask DE. 1994. Tumor growth and neurohormonal signals: current insights into pineal melatonin as a chrono-oncostatic neurohormone. In: Gupta D, Fedor-Freybergh PG, editors. Pathophysiology of immune-neuroendocrine communication circuit. Heidelberg: Mattes Verlag. p 185-192.
11. Brewer GJ. 2000. Neuronal plasticity and stressor toxicity during aging. Exp Gerontol 35:1165-1183.
12. Brusco LI, Márquez M, Cardinali DP. 1998. Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J Pineal Res 25:260-263.
13. Brusco LI, Fainstain I, Marquez M, Cardinali DP. 1999. Effect of melatonin in selected populations of sleep-disturbed patients. Biol Signals Recept 8:126-131.
14. Brusco LI, Márquez M, Cardinali DP. 2000. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett 21:39-42.
15. Brydon L, Roka F, Petit L, De Coppet P, Tissot M, Barrett P, Morgan PJ, Nanoff C, Strosberg AD, Jockers R. 1999. Dual signaling of human Mel1a melatonin receptors via Gi2, Gi3, and Gq/11 proteins. Mol Endocrinol 13:2025-2038.
16. Brydon L, Barrett P, Morgan PJ, Strosberg AD, Jockers B. 2000. Investigation of the human Mel 1a melatonin receptor using antireceptor antibodies. In: Olcese J, editor. Melatonin after four decades. New York: Plenum Publishers/Kluwer Academic. p 215-220.
17. Cajochen C, Kräuchi K, Möri D, Graw P, Wirz-Justice A. 1997. Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis. Am J Physiol 272:B1189-B1196.
18. Cazevieille C, Safa R, Osborne NN. 1997. Melatonin protects primary cultures of rat cortical neurones from NMDA excitotoxicity and hypoxia/reoxygenation. Brain Res 768:120-124.
19. Cohen-Mansfield J, Garfinkel D, Lipson S. 2000. Melatonin for treatment of sundowning in elderly persons with dementia-a preliminary study. Arch Gerontol Geriatr 31:65-76.
20. Cutler NL, Hughes RJ, Singer CM, Sack B, Moffit MT, Lewy AJ. 1997. Insomnia in older individuals: is early awakening the main problem? Sleep Res 26:348.
21. Deigner HP, Haberkorn U, Kinscherf B. 2000. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin Investig Drugs 9:747-764.
22. De la Torre JC, Stefano GB. 2000. Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Rev 34:119-136.
23. Doolen S, Krause DN, Dubocovich ML, Duckles SP. 1998. Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol 345:67-69.
24. Doolen S, Krause DN, Duckles SP. 1999. Estradiol modulates vascular response to melatonin in rat caudal artery. Am J Physiol 276:H1281-H1288.
25. Drew JE, Barrett P, Mercer JG, Moar KM, Canet E, Delagrange P, Morgan PJ. 2001. Localization of the melatonin-related receptor in the rodent brain and peripheral tissues. J Neuroendocrinol 13:453-458.
26. Dubocovich ML. 1983. Melatonin is a potent modulator of dopamine release in the retina. Nature 306:782-784.
27. Dubocovich ML, Masana MI, Benloucif S. 2000. Molecular pharmacology and function of melatonin receptor subtypes. In: Olcese J, editor. Melatonin after four decades. New York: Plenum Publishers/Kluwer Academic. p 181-190.
28. Ekmekcioglu C, Haslmayer P, Philipp C, Mehrabi MR, Glogar HD, Grimm M, Leibetseder VJ, Thalhammer T, Marktl W. 2001. Expression of the MT1 melatonin receptor subtype in human coronary arteries. J Becept Signal Transduct Res 21:85-91.
29. Ferrari E, Arcaini A, Gornati B, Pelanconi L, Cravello L, Fioravanti M, Solerte SB, Magri F, 2000. Pineal and pituitary-adrenocortical function in physiological aging and senile dementia. Exp Gerontol 35:1239-1250.
30. 1 melatonin receptor in rat retina: evidence for multiple cell targets for melatonin. Neuroscience 93:793-799.
31. 1 melatonin receptor in guinea pig retina. Vis Neurosci 17:63-70.
32. Garcia JJ, Reiter BJ, Ortiz GG, Oh CS, Tang L, Yu BP, Escames G. 1998. Melatonin enhances tamoxifen's ability to prevent the reduction in microsomal membrane fluidity induced by lipid peroxidation. J Membr Biol 162:59-65.
33. Geary GG, Krause DN, Duckles SP. 1997. Melatonin directly constricts rat cerebral arteries through modulation of potassium channels, Am J Physiol Heart Circ Physiol 273:H1530-H1536.
34. Godson C, Reppert SM. 1997. The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. Endocrinology 138:397-404.
35. Gupta D. 1986. Human development and pineal gland. In: Gupta D, Reiter BJ, editors. The pineal gland during development: from fetus to adult. London: Croom-Helm. p 117-133.
36. Haimov I, Laudon M, Zisapel N, Souroujon M, Nof D, Shlitner A, Herer P, Tzischinsky, O. 1994. Sleep disorders and melatonin rhythms in elderly people. Br Med J 309:167.
37. Herzog ED, Block GD. 1999. Keeping an eye on retinal clocks. Chronobiol Int 16:229-247.
38. Hirst GD, Edwards FR. 1989. Sympathetic neuroeffector transmission in arteries and arterioles. Physiol Rev 69:546-604.
39. Iuvone PM, Gan J. 1995. Functional interaction of melatonin receptors and D1 dopamine receptors in cultured chick retinal neurons. J Neurosci 15:2179-2185.
40. Jean-Louis G, Von Gizycki H, Zizi F. 1998a. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res 25:177-183.
41. Jean-Louis G, Zizi F, Von Gizycki H, Taub H. 1998b. Effects of melatonin in two individuals with Alzheimer's disease. Percept Mot Skills 1:331-339.
42. Karppanen H, Lahovaara S, Mannisto P, Vapaatole H. 1975. Plasma renin activity and in vitro synthesis of aldosterone by the adrenal glands of rats with spontaneous, renal, or pinealectomy-induced hypertension. Acta Physiol Scand 94:184-188.
43. Kräuchi K, Cajochen C, Werth E, Wirz-Justice A. 1999. Warm feet promote the rapid onset of sleep. Nature 401:36-37.
44. Kräuchi K, Cajochen C, Werth E, Wirz-Justice A. 2000. Functional link between distal vasodilation and sleep-onset latency? Am J Physiol Begul Integrative Comp Physiol 278:B741-B748.
45. Laitinen JT, Viswanathan M, Vakkuri O, Saavedra JM. 1992. Differential regulation of rat melatonin receptors: selective age-associated decline and lack of melatonin-induced changes. Endocrinology 130:2139-2144.
46. Liu C, Weaver DR, Jin X, Shearman LP, Piesehl RL, Gribkoff VK, Reppert SM. 1997, Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19:91-102.
47. Marchiafava PL, Longoni B. 1999. Melatonin as an antioxidant in retinal photoreceptors. J Pineal Res 26:184-189.
48. Maurer I, Zierz S, Moller HJ. 2000. A selective defect of cytochrome c oxidase is present in brain of Alzheimer's disease patients. Neurobiol Aging 21:455-462.
49. Maurizi CP. 1997. Loss of intraventricular fluid melatonin can explain the neuropathology of Alzheimer's disease. Med Hypotheses 49:153-158.
50. Maurizi CP. 2001. Alzheimer's disease: roles for mitochondrial damage, the hydroxyl radical, and cerebrospinal fluid deficiency of melatonin. Med Hypotheses 57:156-160.
51. Mazzuchelli C, Pannacci M, Nonno B, Lucini V, Fraschini F, Stankov BM. 1996. The melatonin receptor in the human brain: cloning experiments and distribution studies. Mol Brain Res 39:117-126.
52. Mesulam M-M. 1999. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24:521-529.
53. Monti JM, Cardinali DP. 2000. A critical assessment of the melatonin effect on sleep in humans. Biol Signals Becept 9:328-339.
54. Moore BY, 1983. Organization and function of a central nervous system circadian oscillator: the suprachiasmatic hypothalamic nucleus. Fed Proc 42:2783-2785.
55. Nelson CS, Marino JL, Allen CN. 1996. Melatonin receptors activate heteromeric G protein-coupled Kir3 channels. Neuroreport 7:717-720.
56. Olivieri G, Hess C, Savaskan E, Ly C, Meier F, Baysang F, Brockhaus M, Müller-Spahn F. 2001. Melatonin protects SHSY5Y neuroblastoma cells from cobalt induced oxidative stress, neurotoxicity and increased β-amyloid secretion. J Pineal Res 31:320-325.
57. Pacchierotti C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P. 2001. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol 22:18-32.
58. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DLM, Reiter RJ, Efthimiopoulos S, Robakis NK. 1997. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer's amyloid peptide. J Neurosci 17:1683-1690.
59. Pappolla MA, Bozner P, Soto C, Shao H, Robakis N, Zagorski M, Frangione B, Ghiso J. 1998. Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem 273:7185-7189.
60. Pappolla MA, Chyan Y-J, Poeggeler B, Frangione B, Wilson G, Ghiso J, Reiter RJ. 2000. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 107:203-231.
61. Persengiev SP. 2001. The neuroprotective and antiapoptotic effects of melatonin in cerebellar neurons involve glucocorticoid receptor and p130 signal pathway. J Steroid Biochem Mol Biol 77:151-158.
62. Petit L, Lacroix I, De Coppet P, Strosberg AD, Jockers R. 1999. Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3′-5′-monophosphate pathway. Biochem Pharmacol 58:633-639.
63. Pierce ME, Besharse JC. 1985. Circadian regulation of retinomotor movements. I. Interaction of melatonin and dopamine in the control of cone length. J Gen Physiol 86:671-689.
64. Pierpaoli W, Maestroni GJM. 1987. Melatonin: a principal neuroimmunoregulatory anti-stress hormone: its anti-aging effects. Immunol Lett 16:355-362.
65. Régriny O, Delagrange P, Scalbert E, Atkinson J, Lartaud-Idjouadiene I. 1998. Melatonin improves cerebral circulation security margin in rats. Am J Physiol 275:H139-H144
66. Reiter RJ. 1991. Pineal melatonin: cell biology of its synthesis and its physiological interactions. Endocr Rev 12:151-180.
67. Reiter RJ. 1998. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 56:359-384.
68. Reiter RJ. 1999a. Oxidative damage to nuclear DNA: amelioration by melatonin. Neuroendocrinol Lett 20:145-150.
69. Reiter RJ, Cabrera J, Sainz RM, Mayo JC, Manchester LC, Tan DX. 1999b. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and Parkinsonism. Ann NY Acad Sci 890:471-485.
70. Reiter RJ, Acuna-Castroviejo D, Tan D-X, Burkhardt S. 2001, Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann NY Acad Sci 939:200-215.
71. Remé CE, Wirz-Justice A, Terman M. 1991. The visual input stage of the mammalian circadian pacemaking system: I. Is there a clock in the mammalian eye? J Biol Rhythm 6:5-29.
72. 1b melatonin receptor. Proc Natl Acad Sci USA 92:8734-8738.
73. Reppert SM. 1997. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 12:528-531.
74. Rúzsás C, Béla Mess. 2000. Melatonin and aging. A brief survey. Neuroendocrinol Lett 21:17-23.
75. Savaskan E, Olivieri G, Brydon L, Jockers B, Kräuchi K, Wirz-Justice A, Müller-Spahn F. 2001. Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer's disease. Neurosei Lett 308:9-12.
76. Savaskan E, Olivieri G, Meier F, Brydon L, Jockers R, Ravid B, Wirz-Justice A, Müller-Spahn F. 2002a. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 32:59-62.
77. Savaskan E, Wirz-Justice A, Olivieri G, Pache M, Kräuchi K, Brydon L, Jockers R, Müller-Spahn F, Meyer P. 2002b. Distribution of melatonin MT1-receptor in human retina. J Histochem Cytochem 50:519-525.
78. Sharma M, Palacios-Bois J, Schwartz G, Iskandar H, Thakur M, Quirion R, Nair NPV 1989. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 25:305-319.
79. Sugawara T, Sieving PA, Iuvone PM, Bush RA. 1998. The melatonin antagonist luzindole protects retinal photoreceptors from light damage in rat. Invest Ophthalmol Vis Sci 39:2458-2465.
80. Swaab DF, Fliers E, Partimann TS. 1985. The suprachiasmatic nucleus of the human brain in regulation to sex, age and senile dementia. Brain Res 342:37-44.
81. Tosini G. 2000. Melatonin circadian rhythm in the retina of mammals. Chronobiol Int 17:599-612.
82. Van Someren EJW. 2000. Circadian and sleep disturbances in the elderly. Exp Gerontol 35:1229-1237.
83. Vandeputte C, Giummelly P, Atkinson J, Delagrange P, Scalbert E, Capdeville-Atkinson C. 2001. Melatonin potentiates NE-induced vasoconstriction without augmenting cytosolic calcium concentration. Am J Physiol Heart Circ Phyiol 280:H420-H425.
84. Viswanathan M, Laitinen JT, Saavedra JM. 1990. Expression of melatonin receptors in arteries involved in thermoregulation. Proc Natl Acad Sci USA 87:6200-6203.
85. Viswanathan M, Laitinen JT, Saavedra JM. 1993. Vascular melatonin receptors. Biol Signals 2:221-227.
86. 1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport 8:109-112.
87. Weaver DR, Stehle JH, Stopa EG, Reppert SM. 1999. Melatonin receptors in human hypothalamus and pituitary: implications for circadian and reproductive responses to melatonin. J Clin Endocrinol Metab 76:295-301.
88. White MP, Fisher LJ. 1989. Effects of exogenous melatonin on circadian disc shedding in the albino rat retina. Vision Res 29:167-179.
89. Wiechmann AF, Yang XL, Wu SM, Hollyfield JG. 1988. Melatonin enhances horizontal cell sensitivity in salamander retina. Brain Res 453:377-380.
90. Wiechmann AF, Hollyfield JG. 1989. HIOMT-like immunoreactivity in the vertebrate retina: a species comparison. Exp Eye Res 49:1079-1095.
91. Winczyk K, Pawlikowski M, Karasek M. 2001. Melatonin and RZR/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer. J Pineal Res 31:179-182.
92. Wirz-Justice A, Armstrong SM. 1996. Melatonin: nature's soporofic? J Sleep Res 5:137-141.
93. Yang Q, Scalbert E, Delagrange P, Vanhoutte PM, O'Rourke ST. 2001. Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries. Am J Physiol Heart Circ Physiol 280:H76-H82.
94. Youngstedt SD, Kripke DF, Elliott JA, Klauber MR. 2001. Circadian abnormalities in older adults. J Pineal Res 31:264-272.